Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:23:13.914Z.
Calculation as of: 2026-10-06T19:23:13.914Z.
Quote observation: 2026-10-06T19:19:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b70623a88433601380a910b4a26e46749c34683655cbd5a24a177d079a9c6739
PE RATIO
N/A
Market Cap
$2.44M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.32M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Onconetix, Inc. (ONCO) | $2.42M | N/A | N/A | N/A | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.41M | N/A | N/A | N/A | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.44M | N/A | N/A | N/A | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | N/A | N/A | N/A | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.37M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | N/A | N/A | N/A | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.55M | N/A | N/A | N/A | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | N/A | 0.58 | 0.58 | 0.58 |
| iSpecimen Inc. (ISPC)vs › | $2.67M | N/A | N/A | N/A | N/A |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.16M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.67
Forward EPS (Est.)
$-200600.00
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
